ArticleJournal of managed care & specialty pharmacy2023

A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.

Xiao Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.